ALK and non-small cell lung carcinoma: In fact, antibodies against ALK were found in patients with ALK-rearranged ALCL and NSCLC, and a CD8+ cytotoxic T lymphocyte (CTL)-mediated response to ALK peptides was documented in peripheral blood lymphocytes (PBLs) from healthy donors [32,33,34].